DAAs drive down liver transplant rate: First study
Universal access to the antivirals appears to have turned the tide of hepatis C-related transplantation, gastroenterologists say
Government subsidy of direct-acting antivirals for hepatitis C is driving down the rate of liver transplants and deaths from the disease, a registry study suggests.
The previous steady climb in adult transplantation – at a mean rate of 3.5 a year – has been stymied, with 7.9 fewer transplants per annum since PBS listing of the drugs in 2016, researchers say.
They examined data on some 5300 transplants recorded in the Australia and New Zealand Liver and Intestinal Transplant
